Samlyn Capital LLC Makes New $11.73 Million Investment in Nektar Therapeutics (NASDAQ:NKTR)

Samlyn Capital LLC bought a new position in shares of Nektar Therapeutics (NASDAQ:NKTR) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 9,457,887 shares of the biopharmaceutical company’s stock, valued at approximately $11,728,000. Samlyn Capital LLC owned approximately 5.14% of Nektar Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the company. Candriam S.C.A. bought a new position in Nektar Therapeutics during the 2nd quarter worth about $99,000. Victory Capital Management Inc. bought a new position in Nektar Therapeutics during the 2nd quarter worth about $29,000. Rhumbline Advisers increased its holdings in Nektar Therapeutics by 3,377.0% during the 2nd quarter. Rhumbline Advisers now owns 185,116 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 179,792 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Nektar Therapeutics by 2,822.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 551,535 shares of the biopharmaceutical company’s stock worth $684,000 after purchasing an additional 532,663 shares in the last quarter. Finally, Values First Advisors Inc. bought a new position in Nektar Therapeutics during the 2nd quarter worth about $56,000. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Price Performance

Shares of NASDAQ NKTR opened at $1.20 on Tuesday. The stock has a market capitalization of $220.82 million, a price-to-earnings ratio of -1.30 and a beta of 0.60. The business has a 50-day moving average of $1.27 and a 200-day moving average of $1.29. Nektar Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $1.93.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.04). The company had revenue of $23.49 million during the quarter, compared to the consensus estimate of $17.24 million. Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same quarter in the previous year, the business earned ($0.27) EPS. On average, sell-side analysts expect that Nektar Therapeutics will post -0.85 EPS for the current year.

Analyst Ratings Changes

Separately, Rodman & Renshaw started coverage on Nektar Therapeutics in a report on Friday, June 28th. They issued a “buy” rating and a $2.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, Nektar Therapeutics presently has an average rating of “Hold” and a consensus price target of $1.50.

Nektar Therapeutics Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.